Disc Medicine Inc. Common Stock (IRON)
Stock · NASDAQ · Health Care
$56.84as of 10/16/2026
Price chart
Active signals
IRON Signal Track Record
How signals performed across all stocks →What IRON's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +3.6% | 55% | October 6, 2026 |
| Bollinger Band Breakout | 26 | +1.5% | 54% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +0.7% | 56% | September 10, 2026 |
| Bollinger Band Breakdown | 13 | -9.7% | 23% | September 8, 2026 |
| Any 20-session window (baseline) | +2.8% | 58% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formati…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 165
- Website
- www.discmedicine.com/
Fundamentals
- 1-day range
- $56.47$60.48
- Market cap
- $2.97B
- P/E (trailing)
- —
- P/E (forward)
- -7.99
- EPS (trailing)
- $-6.57
- Dividend yield
- —
- Beta
- 0.94
- Avg. volume
- 481.3K
Forecasts
12 analyst ratings
Disc Medicine Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IRONDisc Medicine Inc. Common Stock$56.84▲ 0.34%Market cap $2.97BP/E —$40$99.5
- IMNMImmunome Inc. Common Stock$16.47▼ 5.34%Market cap $2.92BP/E —$13.54$30.06
- QUREuniQure N.V. Ordinary Shares$21.78▼ 3.29%Market cap $3.15BP/E —$8.73$71.5
- MBXMBX Biosciences Inc. Common Stock$49.61▼ 2.17%Market cap $3.19BP/E —$12.94$72.64
- SUPNSupernus Pharmaceuticals Inc. Common Stock$37.88▼ 4.27%Market cap $2.72BP/E —$39.36$59.68
- NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares$19.83▼ 3.83%Market cap $3.23BP/E —$20.91$42.21
- AMLXAmylyx Pharmaceuticals Inc. Common Stock$26.34▼ 4.74%Market cap $2.69BP/E —$10.83$41.14
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IRON Disc Medicine Inc. Common Stock | $2.97B | — | $56.84 | ▲ 0.34% | $40$99.5 |
| IMNM Immunome Inc. Common Stock | $2.92B | — | $16.47 | ▼ 5.34% | $13.54$30.06 |
| QURE uniQure N.V. Ordinary Shares | $3.15B | — | $21.78 | ▼ 3.29% | $8.73$71.5 |
| MBX MBX Biosciences Inc. Common Stock | $3.19B | — | $49.61 | ▼ 2.17% | $12.94$72.64 |
| SUPN Supernus Pharmaceuticals Inc. Common Stock | $2.72B | — | $37.88 | ▼ 4.27% | $39.36$59.68 |
| NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares | $3.23B | — | $19.83 | ▼ 3.83% | $20.91$42.21 |
| AMLX Amylyx Pharmaceuticals Inc. Common Stock | $2.69B | — | $26.34 | ▼ 4.74% | $10.83$41.14 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · 9/16/2026
- Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $86Benzinga · 9/16/2026
- Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Quisel John D · September 15, 2026 · Option Exercise36.0K @ $1.01
- Bitterman Kevin · September 11, 2026 · Option Exercise10.0K @ $38.85
- Bitterman Kevin · September 11, 2026 · Option Exercise7.1K @ $45.69
- Bitterman Kevin · September 11, 2026 · Sale27.1K @ $70.11
- Bitterman Kevin · September 4, 2026 · Sale18 @ $79.96
- Bitterman Kevin · September 4, 2026 · Sale759 @ $79.96
- Bitterman Kevin · September 4, 2026 · Sale912 @ $79.96
- Bitterman Kevin · September 3, 2026 · Sale54 @ $79.98
- Bitterman Kevin · September 3, 2026 · Sale2.3K @ $79.98
- Bitterman Kevin · September 3, 2026 · Sale2.8K @ $79.98
- Bitterman Kevin · September 2, 2026 · Sale2 @ $80.98
- Bitterman Kevin · September 2, 2026 · Sale9 @ $80.98
- Bitterman Kevin · September 2, 2026 · Sale10 @ $80.98
- Bitterman Kevin · September 2, 2026 · Sale511 @ $80.17
- Bitterman Kevin · September 2, 2026 · Sale22.1K @ $80.17
Institutional Ownership
March 31, 2026
- Total shares held
- 40.46M
- Total value held
- $2.48B
- Institutional holders
- 200
- Unknown5.59M
- Unknown2.45M
- Unknown2.27M
- Unknown1.74M
- Unknown1.70M
- Unknown1.55M
- Unknown1.51M
- Unknown1.38M
- Unknown1.35M
- Unknown1.34M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Disc Medicine faces valuation scrutiny and whale activity
Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.
Disc Medicine faces valuation scrutiny and whale activity. Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.